Bristol-Myers Squibb (BMY) Tops Q4 EPS by 28c, Offers FY Guidance, Approves $5B Buyback

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. ZETA
9. DAL
10. TMUS

Go back to Bristol-Myers Squibb (BMY) Tops Q4 EPS by 28c, Offers FY Guidance, Approves $5B Buyback

Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results for 2019

February 6, 2020 7:05 AM EST

Reports Fourth Quarter Revenues of $7.9 Billion; $26.1 Billion for Full Year Posts Fourth Quarter GAAP Loss Per Share of $0.55 and Non-GAAP EPS of $1.22 Completes Acquisition of Celgene; Integration and Synergy Capture on Track Presents Important New Data from Leading Hematology Portfolio at ASH Annual Meeting Announces Two U.S. FDA Filing Acceptances for Opdivo plus Yervoy Regimen Announces $5 Billion Increase to Share Repurchase Authorization Provides Financial Guidance for 2020 and 2021

NEW YORK--(BUSINESS... More